Wikidata

(Q61967093)

(Redirected from Q61967094)
English

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

clinical trial

In more languages

Statements

title
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy (English)
0 references
medical condition
lymphoma
0 references
multiple myeloma
0 references
start time
November 2011
0 references
end time
November 2014
0 references
number of participants
0
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61967093&oldid=2083586056"